Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $231.44, for a total value of $694,320.00. Following the completion of the transaction, the insider directly owned 139,486 shares of the company’s stock, valued at $32,282,639.84. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The stock was sold at an average price of $230.77, for a total value of $378,232.03.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.

Natera Stock Performance

Shares of Natera stock traded down $22.07 on Wednesday, reaching $205.61. 2,452,176 shares of the company were exchanged, compared to its average volume of 1,059,726. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36. The company’s 50-day moving average is $234.95 and its two-hundred day moving average is $195.74. The firm has a market cap of $28.44 billion, a price-to-earnings ratio of -89.79 and a beta of 1.64.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The business’s quarterly revenue was up 34.7% on a year-over-year basis. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Rakuten Investment Management Inc. acquired a new position in Natera in the third quarter valued at approximately $34,096,000. SWS Partners lifted its position in Natera by 11.8% in the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in Natera by 192.5% during the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after buying an additional 5,614 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Natera by 63.2% in the third quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock valued at $23,863,000 after purchasing an additional 57,400 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its stake in shares of Natera by 277.8% in the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after buying an additional 19,576 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NTRA has been the subject of several research analyst reports. Evercore ISI increased their price objective on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Guggenheim upped their price objective on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. BTIG Research lifted their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.